Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
21
08
2021
accepted:
19
01
2022
revised:
23
12
2021
pubmed:
17
2
2022
medline:
13
4
2022
entrez:
16
2
2022
Statut:
ppublish
Résumé
Autologous hematopoietic cell transplantation (auto-HCT) may be performed in multiple myeloma (MM) patients relapsing after a previous auto-HCT. For those without an adequate dose of stored stem cells, remobilization is necessary. This retrospective study included patients who, following disease relapse after the first auto-HCT(s), underwent stem cell remobilization and auto-HCT performed using these cells. There were 305 patients, 68% male, median age at salvage auto-HCT was 59 years. The median time to relapse after the first-line penultimate auto-HCT(s) was 30.6 months, the median follow-up after salvage auto-HCT 31 months. The 2- and 4-year non-relapse mortality (NRM) after the salvage auto-HCT was 5 and 9%, the relapse incidence 56 and 76%, respectively. Overall survival (OS) after 2 and 4 years was 76 and 52%, progression-free survival (PFS) 39 and 15%. In multivariable analysis an increasing interval between the penultimate auto-HCT and relapse was associated with better OS and PFS, later calendar year of salvage auto-HCT with better OS. In conclusion, salvage auto-HCT performed with cells remobilized after a previous auto-HCT was associated with acceptable NRM. The leading cause of failure was disease progression of MM, which correlated with a shorter interval from the penultimate auto-HCT to the first relapse.
Identifiants
pubmed: 35169284
doi: 10.1038/s41409-022-01592-y
pii: 10.1038/s41409-022-01592-y
pmc: PMC8993690
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
633-640Informations de copyright
© 2022. The Author(s).
Références
Bone Marrow Transplant. 2009 Mar;43(5):417-22
pubmed: 18850013
Biol Blood Marrow Transplant. 2016 Jun;22(6):1009-1016
pubmed: 26827659
Eur J Haematol. 2011 Jun;86(6):488-95
pubmed: 21410533
Biol Blood Marrow Transplant. 2013 May;19(5):760-6
pubmed: 23298856
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Am J Hematol. 2006 Jun;81(6):426-31
pubmed: 16680735
Bone Marrow Transplant. 2014 Mar;49(3):416-21
pubmed: 24270389
Biol Blood Marrow Transplant. 2018 May;24(5):930-936
pubmed: 29339268
Cancer. 2006 Mar 1;106(5):1084-9
pubmed: 16456814
J Clin Apher. 2021 Jun;36(3):443-453
pubmed: 33592119
Leuk Lymphoma. 2011 Aug;52(8):1455-62
pubmed: 21657961
Ann Oncol. 2018 Apr 1;29(4):1074
pubmed: 28541409
Cancer. 2012 Jul 15;118(14):3549-55
pubmed: 22086552
Bone Marrow Transplant. 2013 Mar;48(3):425-32
pubmed: 22941384
Br J Haematol. 2011 Jun;153(5):666-8
pubmed: 21275960
Biol Blood Marrow Transplant. 2011 Nov;17(11):1638-45
pubmed: 21565277
Biol Blood Marrow Transplant. 2020 Sep;26(9):1559-1566
pubmed: 32417491
Eur J Haematol. 2017 Jul;99(1):42-50
pubmed: 28370401
Leukemia. 2021 Apr;35(4):1214-1217
pubmed: 32747684
Bone Marrow Transplant. 2019 Mar;54(3):353-367
pubmed: 29988062
Biol Blood Marrow Transplant. 2012 May;18(5):773-9
pubmed: 22062804
Biol Blood Marrow Transplant. 2018 Jul;24(7):1372-1378
pubmed: 29408334
Best Pract Res Clin Haematol. 2019 Mar;32(1):54-64
pubmed: 30927976
Leuk Lymphoma. 2013 Oct;54(10):2200-4
pubmed: 23387937
Leuk Lymphoma. 2009 Sep;50(9):1442-7
pubmed: 19637091
Bone Marrow Transplant. 2013 Apr;48(4):568-73
pubmed: 23000647
J Clin Med Res. 2013 Jun;5(3):174-84
pubmed: 23671543
Bone Marrow Transplant. 2013 Feb;48(2):310-1
pubmed: 22773127
Bone Marrow Transplant. 1998 May;21(9):887-92
pubmed: 9613780
Leukemia. 2014 Apr;28(4):888-93
pubmed: 23852547
Haematologica. 2018 Mar;103(3):514-521
pubmed: 29217776
Biol Blood Marrow Transplant. 2013 Mar;19(3):445-9
pubmed: 23186983